Togo - September 2015 - AMP and the Ministry of Health (MoH) of Togo have been collaborating for 12 years on meningitis surveillance in the country. A workshop held on September 30, 2015 presented the results of the first phase of the PneumoTône project, which assesses the impact of PCV13 on meningitis and pneumonia among all age groups in the Tône and Cinkassé districts in northern Togo.
Pneumococcal infections are among the leading causes of death among children and adults worldwide. In 2010, AMP, in collaboration with Togo’s MoH, launched the first phase of the PneumoTône project. This monitoring study conducted in the districts of Tône and Cinkassé among all age groups of the population has shown that pneumococcus is now the leading cause of acute bacterial meningitis and pneumonia in children and adults in the region.
PCV13 protects against the 13 most common strains of pneumococcus. Gavi, the Vaccine Alliance, supports its introduction in low-resource countries. After its introduction in the routine Expanded Program on Immunization (EPI) in Togo in June 2014, Phase 2 of PneumoTône was launched to assess the impact of the vaccine on pneumonia and meningitis in all age groups in both districts. At the same time, AMP and the Togolese MoH set up a catch-up campaign to vaccine over 95% of children aged 9-59 months in the districts of Tône and Cinkassé with PCV13 and then to measure disease incidence and vaccine effect in the general population of that area.
The workshop on September 30, 2015, attended by all partners, reviewed the results of Phase 1 and early Phase 2 of PneumoTône and detailed next steps in the implementation of the project.
About Agence de Médecine Préventive:
Founded in 1972, the Agence de Médecine Préventive (AMP) is a nonprofit organization dedicated to promoting preventive medicine and public health worldwide. Along with its public-and private-sector partners, AMP aims to enhance scientific knowledge in support of evidence-based health policies; support the introduction and use of vaccines; strengthen immunization service delivery and logistics; develop human and institutional capacity through tailor-made training programs and promote innovation in field vaccinology. For more information, please visit: www.amp-vaccinology.org.
Follow AMP on Twitter.